Previous studies have reported that BTG2 is lowly expressed in many malignancies, e.g., lung cancer, hepatocellular carcinoma and gastric cancer [12–14], and functions as a possible target for malignancy prevention and treatment. This evidence concerns the gene BTG2 and gastric cancer.